Steroidogenic Cytochrome P450 Enzymes As Drug Target

Overview

Journal Toxicol Res

Specialty Toxicology

Date 2024 Jun 24

PMID 38911541

Authors

Changmin Kim

Eunseo Jeong

Yoo-Bin Lee

Donghak Kim

Affiliations

Soon will be listed here.

Abstract

Human cytochrome P450 (CYP) enzymes are composed of 57 individual enzymes that perform monooxygenase activities. They have diverse physiological roles in metabolizing xenobiotics and producing important endogenous compounds, such as steroid hormones and vitamins. At least seven CYP enzymes are involved in steroid biosynthesis. Steroidogenesis primarily occurs in the adrenal glands and gonads, connecting each reaction to substrates and products. Steroids are essential for maintaining life and significantly contribute to sexual differentiation and reproductive functions within the body. Disorders in steroid biosynthesis can frequently cause serious health problems and lead to the development of diseases, such as prostate cancer, breast cancer, and Cushing's syndrome. In this review, we provide current updated knowledge on the major CYP enzymes involved in the biosynthetic process of steroids, with respect to their enzymatic mechanisms and clinical implications for the development of new drug candidates.

References

Lu Q, Liu Y, Long B, Grigoryev D, GIMBEL M, Brodie A . The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer. Breast Cancer Res Treat. 1999; 57(2):183-92. DOI: 10.1023/a:1006225601046. View

Karimaa M, Riikonen R, Kettunen H, Taavitsainen P, Ramela M, Chrusciel M . First-in-Class Small Molecule to Inhibit CYP11A1 and Steroid Hormone Biosynthesis. Mol Cancer Ther. 2022; 21(12):1765-1776. DOI: 10.1158/1535-7163.MCT-22-0115. View

Miller W, Auchus R . The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev. 2010; 32(1):81-151. PMC: 3365799. DOI: 10.1210/er.2010-0013. View

Geller D, Auchus R, Miller W . P450c17 mutations R347H and R358Q selectively disrupt 17,20-lyase activity by disrupting interactions with P450 oxidoreductase and cytochrome b5. Mol Endocrinol. 1999; 13(1):167-75. DOI: 10.1210/mend.13.1.0219. View

Plourde P, Dyroff M, Dowsett M, Demers L, Yates R, Webster A . ARIMIDEX: a new oral, once-a-day aromatase inhibitor. J Steroid Biochem Mol Biol. 1995; 53(1-6):175-9. DOI: 10.1016/0960-0760(95)00045-2. View

Valentin-Goyco J, Liu J, Peng H, Oommen J, Auchus R . Selectivity of osilodrostat as an inhibitor of human steroidogenic cytochromes P450. J Steroid Biochem Mol Biol. 2023; 231:106316. PMC: 10757358. DOI: 10.1016/j.jsbmb.2023.106316. View

Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, Shimatsu A . Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet Diabetes Endocrinol. 2020; 8(9):748-761. DOI: 10.1016/S2213-8587(20)30240-0. View

Lipton A, Demers L, Harvey H, Kambic K, Grossberg H, Brady C . Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer. Cancer. 1995; 75(8):2132-8. DOI: 10.1002/1097-0142(19950415)75:8<2132::aid-cncr2820750816>3.0.co;2-u. View

Guengerich F . Cytochrome P450: what have we learned and what are the future issues?. Drug Metab Rev. 2004; 36(2):159-97. DOI: 10.1081/dmr-120033996. View

10.

Creemers S, Feelders R, de Jong F, Franssen G, de Rijke Y, Van Koetsveld P . Levoketoconazole, the 2S,4R Enantiomer of Ketoconazole, a New Steroidogenesis Inhibitor for Cushing's Syndrome Treatment. J Clin Endocrinol Metab. 2021; 106(4):e1618-e1630. DOI: 10.1210/clinem/dgaa989. View

11.

Kok R, Timmerman M, Wolffenbuttel K, Drop S, de Jong F . Isolated 17,20-lyase deficiency due to the cytochrome b5 mutation W27X. J Clin Endocrinol Metab. 2010; 95(3):994-9. DOI: 10.1210/jc.2008-1745. View

12.

Lacroix A, Feelders R, Stratakis C, Nieman L . Cushing's syndrome. Lancet. 2015; 386(9996):913-27. DOI: 10.1016/S0140-6736(14)61375-1. View

13.

Basu S, Tindall D . Androgen action in prostate cancer. Horm Cancer. 2011; 1(5):223-8. PMC: 10358150. DOI: 10.1007/s12672-010-0044-4. View

14.

Amaral C, Varela C, Azevedo M, da Silva E, Roleira F, Chen S . Effects of steroidal aromatase inhibitors on sensitive and resistant breast cancer cells: aromatase inhibition and autophagy. J Steroid Biochem Mol Biol. 2013; 135:51-9. DOI: 10.1016/j.jsbmb.2012.12.017. View

15.

Simpson E . Sources of estrogen and their importance. J Steroid Biochem Mol Biol. 2003; 86(3-5):225-30. DOI: 10.1016/s0960-0760(03)00360-1. View

16.

Khosla S, Oursler M, Monroe D . Estrogen and the skeleton. Trends Endocrinol Metab. 2012; 23(11):576-81. PMC: 3424385. DOI: 10.1016/j.tem.2012.03.008. View

17.

Estrada D, Skinner A, Laurence J, Scott E . Human cytochrome P450 17A1 conformational selection: modulation by ligand and cytochrome b5. J Biol Chem. 2014; 289(20):14310-20. PMC: 4022897. DOI: 10.1074/jbc.M114.560144. View

18.

Guengerich F . Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J. 2006; 8(1):E101-11. PMC: 2751428. DOI: 10.1208/aapsj080112. View

19.

Perez E, Josse R, Pritchard K, Ingle J, Martino S, Findlay B . Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol. 2006; 24(22):3629-35. DOI: 10.1200/JCO.2005.05.4882. View

20.

DeVore N, Scott E . Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001. Nature. 2012; 482(7383):116-9. PMC: 3271139. DOI: 10.1038/nature10743. View